A61P 9/04
Inotropic agents, i.e. stimulants of cardiac contraction
Official title: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
A61P9/04 (Inotropic agents, i.e. stimulants of cardiac contraction) appears on 7,424 US grants and 10,978 published applications in this corpus.
Search patents in A61P- Granted patents
- 7,424
- Published applications
- 10,978
- Assignees
- 2,711
- Inventors
- 17,737
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 8 | 0 |
| 1978 | 5 | 0 |
| 1979 | 6 | 0 |
| 1980 | 7 | 0 |
| 1981 | 15 | 0 |
| 1982 | 13 | 0 |
| 1983 | 13 | 0 |
| 1984 | 22 | 0 |
| 1985 | 35 | 0 |
| 1986 | 26 | 0 |
| 1987 | 46 | 0 |
| 1988 | 38 | 0 |
| 1989 | 33 | 0 |
| 1990 | 17 | 0 |
| 1991 | 21 | 0 |
| 1992 | 23 | 0 |
| 1993 | 19 | 0 |
| 1994 | 15 | 0 |
| 1995 | 22 | 0 |
| 1996 | 20 | 0 |
| 1997 | 26 | 0 |
| 1998 | 35 | 0 |
| 1999 | 42 | 0 |
| 2000 | 71 | 0 |
| 2001 | 106 | 40 |
| 2002 | 154 | 192 |
| 2003 | 161 | 378 |
| 2004 | 147 | 567 |
| 2005 | 165 | 475 |
| 2006 | 204 | 522 |
| 2007 | 234 | 558 |
| 2008 | 255 | 637 |
| 2009 | 276 | 757 |
| 2010 | 415 | 809 |
| 2011 | 434 | 699 |
| 2012 | 461 | 705 |
| 2013 | 532 | 548 |
| 2014 | 548 | 542 |
| 2015 | 442 | 484 |
| 2016 | 376 | 502 |
| 2017 | 366 | 416 |
| 2018 | 293 | 379 |
| 2019 | 270 | 349 |
| 2020 | 251 | 311 |
| 2021 | 211 | 249 |
| 2022 | 143 | 220 |
| 2023 | 116 | 178 |
| 2024 | 114 | 203 |
| 2025 | 109 | 163 |
| 2026 | 59 | 95 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Alkylsulfenyl thiocarbonates: precursors to hydropersulfides potently attenuate oxidative stress15 Sep 2026US 12,735,385 B2The Johns Hopkins University
- Methods for the production of cardiac fibroblasts25 Aug 2026US 12,714,728 B2FUJIFILM Cellular Dynamics, Inc.
- 5-(thiophen-2-yl)-1 H-tetrazole derivative as BCKDK inhibitors useful for treating various diseases25 Aug 2026US 12,715,863 B2Pfizer Inc.
- Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for use in intervention and therapy of congestion in a patient in need thereof25 Aug 2026US 12,715,911 B2Adrenomed AG
- Compositions and methods for treating heart failure18 Aug 2026US 12,708,658 B2Zensun (Shanghai) Science & Technology, Co., Ltd.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Methods of treating heart failure24 Sep 2026US 2026/0284030 A1Children's Medical Center Corporation
- Methods of treatment with finerenone17 Sep 2026US 2026/0272897 A1
- Methods of treatment with finerenone17 Sep 2026US 2026/0272898 A1
- Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline17 Sep 2026US 2026/0274989 A14TEEN4 Pharmaceuticals GmbH
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008
- Modified antibody variable domains462US 5,766,886 AXoma Corporation · 1998